A nurse is reviewing the case of a patient with advanced melanoma. The patient exhibits a lesion with a Breslow thickness of 3.2 mm, elevated LDH levels, and a suspicious liver lesion. Considering these findings, which nursing intervention is most appropriate for managing the patient's current condition?

B) Collaborate with the healthcare team to prepare the patient for a liver biopsy

A) Educate the patient on the importance of sunscreen use to prevent further skin damage

B) Collaborate with the healthcare team to prepare the patient for a liver biopsy

C) Schedule routine follow-up appointments to monitor skin changes

D) Encourage increased oral fluid intake to manage nausea

A patient with a confirmed high-risk melanoma and potential metastasis is experiencing persistent fatigue and intermittent nausea. As the nurse, which initial intervention is most appropriate to address these symptoms while awaiting further diagnostic results?

B) Administer prescribed antiemetic medication and monitor for relief.

A) Encourage the patient to increase fluid intake and maintain a balanced diet.

B) Administer prescribed antiemetic medication and monitor for relief.

C) Educate the patient about the importance of adequate rest and sleep hygiene.

D) Suggest the patient engage in light exercise to improve energy levels.

A patient with Stage IV metastatic melanoma in the liver reports increased fatigue and decreased appetite. What is the most appropriate nursing intervention to address these symptoms while considering the overall treatment plan?

C) Discuss dietary modifications to enhance nutritional intake

A) Encourage increased physical activity to boost energy levels

B) Educate the patient about the side effects of immunotherapy

C) Discuss dietary modifications to enhance nutritional intake

D) Suggest the use of complementary therapies such as herbal supplements

A patient with newly diagnosed Stage IV metastatic melanoma is experiencing increased fatigue and decreased appetite. Which nursing intervention is most appropriate to address these symptoms and improve the patient's quality of life?

A) Encourage the patient to eat small, frequent meals high in protein and calories.

B) Suggest the patient increase physical activity to combat fatigue.

C) Recommend the patient eliminate all dietary fats to improve liver function.

D) Advise the patient to take over-the-counter supplements to boost energy levels.

A patient undergoing immunotherapy for melanoma has developed signs of hepatic dysfunction, including jaundice and elevated liver enzymes. The clinical team decides to hold the immunotherapy and initiate corticosteroid treatment. As the nurse caring for this patient, which nursing intervention should be prioritized to support liver function and monitor therapy effectiveness?

B) Educate the patient on the importance of avoiding alcohol

A) Administer acetaminophen as needed for discomfort

B) Educate the patient on the importance of avoiding alcohol

C) Schedule daily liver function tests to monitor progress

D) Encourage the patient to increase protein intake

A patient receiving a PD-1 inhibitor for metastatic melanoma develops symptoms of jaundice, pruritus, and dark urine two weeks into treatment. Laboratory findings indicate elevated bilirubin, AST, and ALT levels. Which nursing intervention is the most appropriate to prioritize in this situation?

A) Encourage the patient to maintain adequate hydration and avoid hepatotoxic substances.

B) Administer antiemetic medications to manage potential nausea from elevated bilirubin.

C) Instruct the patient to increase protein intake to aid liver function recovery.

D) Recommend over-the-counter pain relief for discomfort associated with pruritus.

A patient undergoing corticosteroid therapy for immune-related hepatitis presents with new onset of fatigue, mild abdominal discomfort, and laboratory findings indicating anemia and leukocytosis. What is the nurse's priority intervention in managing this patient's care?

B) Collaborate with the healthcare provider to adjust the corticosteroid dosage and investigate the cause of anemia

A) Increase the fluid intake to prevent dehydration associated with corticosteroid use

B) Collaborate with the healthcare provider to adjust the corticosteroid dosage and investigate the cause of anemia

C) Educate the patient on the importance of rest to manage fatigue

D) Administer prescribed analgesics to alleviate abdominal discomfort

A patient with a history of melanoma is being treated with corticosteroids for immune-related hepatitis. Two weeks into treatment, the patient presents with new onset fatigue and mild abdominal discomfort, along with laboratory findings of anemia and leukocytosis. What is the priority nursing intervention in this scenario?

B) Monitor the patient's hemoglobin levels and report any further decreases to the healthcare provider.

A) Educate the patient on the importance of continuing corticosteroid therapy to manage hepatitis.

B) Monitor the patient's hemoglobin levels and report any further decreases to the healthcare provider.

C) Assess the patient's dietary intake and encourage iron-rich foods to address potential nutritional anemia.

D) Prepare the patient for possible transfusion therapy based on current hemoglobin levels.

A patient with a history of melanoma on corticosteroid therapy presents with fatigue, dizziness, pallor, bruising, and lab findings of anemia and thrombocytopenia. Considering these symptoms and lab results, what is the nurse's priority intervention?

C) Notify the healthcare provider about the need to adjust corticosteroid therapy.

A) Educate the patient about increasing dietary iron intake to address anemia.

B) Monitor the patient's blood pressure and educate on safety measures to prevent falls.

C) Notify the healthcare provider about the need to adjust corticosteroid therapy.

D) Encourage the patient to maintain hydration to manage symptoms of dizziness.

A patient returns with persistent fatigue, new bruising, dizziness upon standing, and laboratory findings indicating anemia and thrombocytopenia. Considering these signs and symptoms, which nursing intervention is the most appropriate to prioritize?

B) Educating the patient on safety measures to prevent falls due to dizziness and orthostatic hypotension.

A) Administering a blood transfusion to address the low hemoglobin and hematocrit levels.

B) Educating the patient on safety measures to prevent falls due to dizziness and orthostatic hypotension.

C) Monitoring the patient's liver function tests closely due to potential progression of liver disease.

D) Preparing the patient for a bone marrow biopsy to investigate the cause of myelosuppression.

Melanoma - Nursing Case Study

Pathophysiology

• Primary mechanism: Uncontrolled proliferation of melanocytes occurs due to DNA damage, often from UV radiation, causing mutations in genes such as BRAF and NRAS. This leads to the formation of malignant tumors in the skin.

• Secondary mechanism: The loss of tumor suppressor genes like p53 further disrupts cell cycle regulation, allowing abnormal melanocyte growth and evasion of apoptosis, which contributes to tumor progression.

• Key complication: Metastasis arises when melanoma cells invade surrounding tissues and enter the lymphatic system or bloodstream, spreading to distant organs, which significantly worsens prognosis and complicates treatment.

Patient Profile

Demographics:

58-year-old male, outdoor construction worker

History:

• Key past medical history: History of actinic keratosis, hypertension

• Current medications: Lisinopril 10 mg daily, Aspirin 81 mg daily

• Allergies: Penicillin

Current Presentation:

• Chief complaint: Increasingly painful and bleeding mole on the upper back

• Key symptoms: Enlarging dark lesion with irregular borders, fatigue, occasional nausea

• Vital signs: Blood pressure 145/92 mmHg, heart rate 102 bpm, respiratory rate 20 breaths per minute, temperature 99.1°F, oxygen saturation 95% on room air

Section 1

As the patient's case progresses, the initial assessment findings reveal further insights into the severity and extent of his melanoma. Upon physical examination, the lesion on the patient's upper back measures approximately 2.5 cm in diameter with irregular, asymmetrical borders and varied pigmentation, ranging from dark brown to black. The lesion exhibits signs of ulceration and bleeding, indicative of an advanced stage of melanoma. Palpation of regional lymph nodes reveals slight enlargement, particularly in the axillary and cervical areas, suggesting possible lymphatic involvement. The patient also reports persistent fatigue and intermittent nausea, which may suggest systemic involvement.

Laboratory tests are conducted to provide a clearer picture of the patient's condition. Blood work reveals a slightly elevated lactate dehydrogenase (LDH) level, which can be indicative of tissue damage or metastasis. A skin biopsy confirms the diagnosis of melanoma with a Breslow thickness of 3.2 mm, classifying it as a high-risk melanoma for metastasis. Imaging studies, including a chest X-ray and abdominal ultrasound, are performed to assess for metastatic spread. The chest X-ray shows no obvious signs of metastasis, but the ultrasound reveals a suspicious lesion in the liver, warranting further investigation with a CT scan.

These findings raise significant concerns about potential metastasis, requiring careful clinical reasoning to prioritize further diagnostic testing and treatment planning. The presence of an elevated LDH and a suspicious liver lesion necessitates a multidisciplinary approach involving oncology, dermatology, and radiology to confirm metastatic spread and determine appropriate systemic treatment options. The patient's journey now hinges on the results of the CT scan and potential biopsy of the liver lesion, which will guide the next steps in managing this complex case.

Section 2

Following the initial assessment and diagnostic tests, the patient undergoes a CT scan of the abdomen to further evaluate the suspicious liver lesion. The CT scan reveals multiple small lesions scattered throughout the liver, consistent with metastatic disease. Additionally, there is evidence of a small amount of ascites, reinforcing the suspicion of systemic involvement. Given these findings, a percutaneous liver biopsy is performed, confirming the presence of metastatic melanoma in the liver. This development marks a significant progression in the patient's condition, indicating Stage IV melanoma.

In light of the new diagnostic results, the patient's clinical status is carefully monitored. Vital signs remain stable, with a blood pressure of 118/76 mmHg, heart rate of 82 beats per minute, respiratory rate of 18 breaths per minute, and a temperature of 37.1°C. However, the patient reports an increase in fatigue and a decrease in appetite, which may be attributed to the hepatic involvement and overall disease burden. Additionally, laboratory tests show a further rise in LDH levels, now at 280 U/L, which correlates with the extent of metastatic disease.

These developments necessitate a reevaluation of the treatment plan, focusing on systemic therapy options to address the metastatic spread. The oncology team discusses the potential for initiating immunotherapy, given its success in managing advanced melanoma. Concurrently, supportive care measures are considered to address the patient's symptoms and improve quality of life. The multidisciplinary team must now weigh the benefits and risks of the proposed interventions, taking into account the patient's overall health status and preferences, as they prepare for a complex journey ahead.

Section 3

As the treatment plan is implemented, the patient begins immunotherapy with a PD-1 inhibitor, aiming to enhance the immune system's ability to target and destroy melanoma cells. Initially, the patient tolerates the therapy well, with no acute allergic reactions or infusion-related complications. However, within two weeks of starting treatment, the patient develops new symptoms, including mild jaundice, pruritus, and a darkening of the urine. These signs prompt an urgent reassessment, with liver function tests revealing an increase in bilirubin to 3.5 mg/dL, AST at 85 U/L, and ALT at 95 U/L, indicating hepatic dysfunction likely exacerbated by the metastatic disease and possibly aggravated by immunotherapy.

The clinical team, aware of the potential hepatotoxic effects of immunotherapy, considers the possibility of immune-related hepatitis. This complication requires careful management to balance the continuation of potentially life-prolonging therapy against the risk of further liver damage. The decision is made to temporarily hold the immunotherapy and initiate corticosteroid treatment, which is a standard approach to manage immune-related adverse effects. The patient is also advised to maintain adequate hydration and avoid hepatotoxic substances, including alcohol and certain medications, to support liver recovery.

Throughout this challenging period, the patient is closely monitored for any signs of improvement or further deterioration. Regular follow-up appointments are scheduled to track liver function tests, and a multidisciplinary team, including hepatologists and oncologists, collaborates to optimize the patient's care plan. The patient's response to the corticosteroid treatment will be pivotal in determining the feasibility of resuming immunotherapy or exploring alternative therapeutic options. This phase of treatment underscores the complexity of managing advanced melanoma with systemic involvement and the importance of vigilant monitoring and interdisciplinary cooperation.

Section 4

Two weeks after initiating corticosteroid treatment, the patient returns for a follow-up appointment. During the visit, it is noted that the patient's jaundice has slightly improved, and the pruritus has diminished, suggesting a positive initial response to the corticosteroids. However, the patient reports new onset of fatigue and mild abdominal discomfort. Vital signs reveal a blood pressure of 110/70 mmHg, pulse rate of 88 beats per minute, respiratory rate of 18 breaths per minute, and temperature of 98.6°F. Physical examination indicates mild right upper quadrant tenderness, but no significant hepatomegaly or splenomegaly is palpated.

New laboratory results show a modest decrease in bilirubin levels to 2.8 mg/dL, with AST reduced to 70 U/L and ALT to 80 U/L, indicating a trend towards improvement. However, the complete blood count reveals a decrease in hemoglobin to 10.5 g/dL, hematocrit to 32%, and mild leukocytosis with a white blood cell count of 12,000/mm³. These findings raise concerns about potential anemia and an inflammatory process possibly related to the patient's underlying melanoma or an adverse effect of ongoing corticosteroid therapy.

Given these developments, the clinical team deliberates on the balance between continuing corticosteroid therapy to manage immune-related hepatitis and addressing the new symptoms of fatigue and abdominal discomfort. A decision is made to adjust the corticosteroid dosage while concurrently investigating the cause of anemia and leukocytosis. A referral to a hematologist is considered to rule out any hematological involvement due to melanoma or as a side effect of treatment. The patient's situation highlights the intricate interplay of managing adverse effects while ensuring the primary malignancy remains controlled, prompting further refinement of the therapeutic approach.

Section 5

Two weeks later, the patient returns to the clinic for further evaluation. During this visit, the patient reports persistent fatigue and has noticed a new onset of bruising on her arms and legs that she cannot attribute to any specific trauma. She also mentions feeling dizzy upon standing, which has been more frequent over the past few days. Her vital signs reveal a blood pressure of 100/65 mmHg with a notable orthostatic drop, pulse rate of 92 beats per minute, respiratory rate of 20 breaths per minute, and temperature of 98.4°F. On physical examination, the patient exhibits pallor and multiple ecchymoses on the extremities. There is still mild tenderness in the right upper quadrant, but no new abdominal findings.

New laboratory results show a further decline in hemoglobin to 9.0 g/dL and hematocrit down to 28%, confirming the progression of anemia. Platelet count has decreased to 110,000/mm³, suggesting the development of thrombocytopenia. Liver function tests remain stable with bilirubin at 2.5 mg/dL, AST at 65 U/L, and ALT at 75 U/L, indicating that liver inflammation is still under control. However, the persistent leukocytosis, now at 13,500/mm³, along with the new hematological abnormalities, raises concerns about potential bone marrow suppression or an autoimmune process exacerbated by the corticosteroid therapy.

These findings necessitate a multidisciplinary approach, including consultation with a hematologist to explore potential causes such as corticosteroid-induced myelosuppression, a paraneoplastic syndrome associated with melanoma, or an autoimmune hematological disorder. The clinical team must weigh the risks of continuing corticosteroid therapy against the potential benefits, considering alternative immunosuppressive treatments if necessary. This complex scenario underscores the need for careful monitoring and adjustment of the therapeutic regimen to address the evolving complications while keeping the primary malignancy in check. The patient's case exemplifies the challenges of managing treatment side effects while maintaining vigilance for new, unexpected developments in her clinical status.